View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 12, 2021updated 22 Nov 2021 8:43am

I-Mab’s plonmarlimab lowers mortality rate in Phase II/III Covid-19 trial

Nearly 83.6% of subjects in the plonmarlimab arm had a higher mechanical ventilation free rate by day 30.

I-Mab has reported positive interim results from the Phase II/III trial of plonmarlimab (TJM2 or TJ003234) to treat cytokine release syndrome (CRS) in severe Covid-19 patients in the US.

Discovered and developed by I-Mab, plonmarlimab is a neutralising antibody that targets a cytokine called human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is involved in inflammation.

The drug attaches to and hinders GM-CSF from binding to its receptor, to prevent downstream signalling and target cell activation for CRS prevention and treatment.

The ongoing, double-blind, placebo-controlled, randomised Phase II/III trial is assessing the therapeutic role of plonmarlimab in patients with severe Covid-19.

The objective of the trial is to establish safety, efficacy and effects on cytokine levels induced by a single dose of 6mg/kg of plonmarlimab compared to placebo.

According to the preliminary interim analysis data, 83.6% of subjects receiving plonmarlimab had an increased mechanical ventilation free (MVF) rate versus 76.7% in the placebo arm by day 30.

Furthermore, the drug lowered mortality rate, with 4.9% and 13.3% noted in the plonmarlimab and placebo arms, respectively, by day 30.

Subjects receiving the treatment had increased recovery rates and lower time to recovery and time in hospital as against those on placebo.

I-Mab noted that the degree of the clinical improvements was in line with those seen with lenzilumab in a similar subject population.

A decline in plasma levels of major pro-inflammatory cytokines and chemokines linked to CRS was noted in subjects in the plonmarlimab arm versus the placebo arm.

Biomarker data were similar to the reported clinical data. In addition, a transient rise in neutrophil to lymphocyte ratio (NLR) related to disease aggravation was seen only in the placebo group.

In the trial, plonmarlimab was well-tolerated in all subjects without any substantial safety issues.

I-Mab CEO Dr Joan Shen said: “Plonmarlimab has shown very promising results from the interim data analysis in our Phase II/III trial, and we intend to continue advancing the study in the US at this critical juncture of the Covid-19 pandemic and continue exploring other clinical opportunities associated with CRS.”

In March last year, I-Mab announced plans to develop TJM2 for the treatment of cytokine storm caused due to severe and critical Covid-19 infection.

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU